Prestige Brands (PBH) Closes Insight Pharmaceuticals Purchase

Prestige Brands (NYSE: PBH) announced that it has closed the previously announced acquisition of Insight Pharmaceuticals Corporation (“Insight”), a marketer and distributor of feminine care and other over-the-counter (“OTC”) healthcare products.

The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. The acquisition will extend Prestige’s portfolio of iconic OTC brands to include a leading feminine care platform in the U.S. and Canada anchored by Monistat®, the #1 brand in OTC yeast infection treatment. The acquisition will also add brands to Prestige’s cough/cold, pain relief, ear care and dermatological platforms. This transaction is expected to result in pro forma revenues and adjusted EBITDA of approximately $800 million and $300 million, respectively, for the Company in fiscal 2015. The purchase of Insight will be immediately accretive to the Company’s earnings per share and free cash flow per share, exclusive of transaction, integration and purchase accounting items.

Sawaya Segalas & Co., LLC acted as exclusive financial advisor to Prestige Brands on this transaction.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Western Digital (WDC) Tops Q3 EPS by 42c; offers guidance